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CTX-M–Type 
β β-Lactamases
Affect Community
Escherichia coli
Treatment, Greece 
To the Editor: In recent years, a
new group of extended-spectrum β-
lactamases (ESBLs), the CTX-
M–type enzymes, has emerged among
Enterobacteriaceae (1). These
enzymes are much more active
against cefotaxime than against cef-
tazidime and exhibit greater suscepti-
bilty to tazobactam than to clavu-
lanate. Currently, the CTX-M family
includes at least 30 alleles, which may
be clustered on the basis of sequence
similarity into four major evolution-
ary lineages (2). These enzymes were
first detected in South America,
Germany, and France, and subsequent
reports found them to be in several
European countries as well as in the
Far East and North and South
America (1–5). All of these studies
have described the production of
CTX-M–type  β-lactamases in
Enterobacteriaceae  that have been
isolated from patients with hospital
infections, whereas surveys assessing
countrywide prevalence of CTX-M
clusters in community-acquired infec-
tions have not been carried out. We
report the dissemination of various
CTX-M–type enzymes in clinical iso-
lates of Escherichia coli recovered
from community-acquired infections
in two large regions of Greece. 
The microbiology databases of
two healthcare systems in Greece that
serve as tertiary care centers for their
region (University Hospital of Larissa
and Hippokration University Hospital
of Thessaloniki) were prospectively
searched from January to September
2003. From almost 75,000 outpatient
visits, we tested E. coli isolates that
were recovered from patients with
community-acquired infections and
classified as ESBL producers by the
E-test ESBLscreen method with cefo-
taxime and ceftazidime plus clavu-
lanate. Community-acquired E. coli
infections were defined as those con-
tracted outside a hospital environment
for persons with no history of hospi-
talization, surgery, or outpatient care
during the previous 30 days. 
ESBL-positive isolates for which
the cefotaxime MICs were at least
eightfold higher than those of cef-
tazidime by agar dilution were saved
and stored at –70°C. Results of
antimicrobial susceptibility tests and
ESBL screening and confirmatory
tests were used to characterize the
phenotypes of the isolates. Molecular
analysis included polymerase chain
reaction (PCR) detection with primers
producing an 873-bp amplicon of the
blaCTX-M gene (6), sequencing on both
strands of PCR products, pulsed-field
gel electrophoresis of XbaI chromoso-
mal digests, plasmid analysis, and
transferability experiments of cefo-
taxime resistance.
Treatment outcomes were assessed
by reviewing the medical records of
all patients for whom a culture yield-
ed a strain of E. coli producing a
CTX-M–type ESBL. Patients’ data
included demographic details, pres-
ence of existing illness, symptoms,
laboratory test results, history of sur-
gery, and exposure to extended-spec-
trum cephalosporins <30 days before
the positive culture. The antimicrobial
treatment regimen was recorded,
including the agent or agents adminis-
tered, the duration of treatment, and
clinical response. 
During the study period, 14 com-
munity-acquired E. coli isolates (10 in
the region of Larissa and 4 in the
region of Thessaloniki) were recov-
ered; the E-test ESBL screen test con-
firmed that these isolates were ESBL
producers, and cefotaxime MICs were
at least eightfold higher than those of
ceftazidime. A CTX-M–type determi-
nant was detected by PCR in 10 iso-
lates (6 from Larissa and 4 from
Thessaloniki). Sequencing their
amplicons revealed that three of them
were CTX-M-1 producers, and seven
were CTX-M-3 producers. Geno-
typing showed that all of these iso-
lates were unrelated. MICs of cefo-
taxime were always >128  µg/mL,
whereas MICs of ceftazidime ranged
from 0.5 µg/mL to 16 µg/mL. All iso-
lates were sensitive to cefoxitin and
piperacillin/tazobactam. However, the
two laboratories reported them as
being ESBL producers and recom-
mended that β-lactam antibiotics,
with the exception of carbapenems,
not be used in their treatment. Several
isolates exhibited additional resist-
ance to co-trimoxazole, ciprofloxacin,
tetracycline, or gentamicin, but all
were susceptible to the other amino-
glycosides. The blaCTX-M determinants
were transferable to E. coli by conju-
gation in all but one case, along with
other antimicrobial resistance deter-
minants, with transfer frequencies that
ranged from 8.3 x 10–5 to 2.2 x 10–2.
Transconjugants contained one to
three plasmids of varying size, rang-
ing from 10 to 130 kb.
CTX-M–positive isolates were
recovered from five children and five
adults. Patients did not have typical
risk factors, except for a chronic
hematologic malignancy in one
patient. Nine of the patients had
severe urinary tract infections and
received courses of amikacin or
ciprofloxacin. One female patient had
a purulent perianal infection. Results
of blood and wound cultures from
samples obtained at admission yield-
ed the CTX-M–positive E. coli strain.
She was given amikacin and clin-
damycin, and her condition gradually
improved.
β-lactam antibiotics are the most
common antimicrobial agents used in
the community setting. The docu-
mented CTX-M–positive isolates
exhibited plasmid-mediated resist-
ance that affected the antimicrobial
activity of all penicillins and
cephalosporins as well as of several
alternative antimicrobial agents used
to treat community-acquired E. coli
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infections. The spread of CTX-
M–positive bacteria considerably
changes the way we think about treat-
ing community-acquired infections
and limits the oral antibiotics that may
be administered. This finding has
major implications for treating chil-
dren, who should not be given fluoro-
quinolones and tetracyclines. 
The observation that different
blaCTX-M alleles, located on plasmids
of different sizes, were involved in
clinical infections caused by distinct
E. coli clones implies that CTX-M
enzymes may become widespread in
the community. Apossible association
of  blaCTX-M genes with insertion
sequences like ISEcp1B might have
contributed to the enhanced expres-
sion and mobilization of blaCTX-M
genes among E. coli isolates (7). The
apparent dissemination of CTX-M
producers could represent a substan-
tial barrier in the treatment of commu-
nity-acquired infections. Additionally,
severely ill patients treated in the out-
patient setting may transmit such
resistant organisms to hospitalized
patients. 
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Age and
Transmissible
Spongiform
Encephalopathies
To the Editor: Bacchetti (1) notes
“Our findings suggest that the possi-
bility should not be discounted that
biological factors peaking in the third
decade of life may promote variant
Creutzfeldt-Jakob disease (vCJD)
prion replication and consequent
development of disease.” Such age
specificity of disease risk may be a
general feature of transmissible
spongiform encephalopathies, which
suggests that a general mechanism
should be sought. A likely candidate
for this mechanism is senescence-
related immune system defects.
In a study of scrapie outbreaks in
four sheep flocks, the incidence of
clinical cases peaked in sheep 2–3
years of age, despite very different
forces -of- infection at work and very
large differences in disease incidence
(2). Similar age specificity has been
observed in cattle infected with
bovine spongiform encephalopathy
(3), which is believed to be the causal
agent of variant Creutzfeldt-Jakob
disease. There is evidence that an age-
specific peak in prevalence also
occurs in chronic wasting disease, a
laterally transmitted spongiform
encephalopathy of North American
cervids, specifically elk, mule deer,
and white-tailed deer. For example,
data on prevalence of chronic wasting
disease in mule deer (Figures 4B and
4A of [4]) suggest the existence of
age-specific peaks. In aggregate,
these observations suggest that a gen-
eral mechanism might produce the
marked decline in disease risk as age
increases.
In 1979, Dickinson and Outram (5)
conjectured that, in some experi-
ments, scrapie responsiveness is the
opposite of what one normally
expects with an infection, “raising the
possibility that, far from being inimi-
cal, some part of the host’s immune
system is essential and may even play
the role of a Trojan Horse for these
agents when infection occurs by a
peripheral route.” This theory appears
well founded for transmissible
spongiform encephalopathies in gen-
eral. Disease-associated forms of
resistant prion protein (PrPRes) are
likely transported from the gut to lym-
phoid tissue by cells such as migrat-
ing intestinal dendritic cells (6). Once
in the lymphoid tissue PrPRes appears
to be amplified by follicular dendritic
cells (6) and then enters the nervous
system. Defects in either the comple-
ment pathway or follicular dendritic
cells result in resistance to peripheral
scrapie infection (7,8), and this resist-
ance likely occurs for peripheral
transmissible spongiform encephalo-
pathy infections in general. 
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